公司資料
Larimar Therapeutics 股價、新聞與催化劑
- 股票代碼:
- LRMR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
4.18 USD (+0.48%)
收盤價
最後更新: 2026年8月21日
343M USD
市值
股價為何變動
As of Aug 21, 2026, LRMR closed up 0.48% at $4.18. No new same-company headline was identified in the current news window.
公司概覽
Intracellular Protein Delivery
Larimar Therapeutics develops fusion proteins that deliver functional biological material into cells. Its lead program addresses a rare disease caused by deficiency of the intracellular protein frataxin.
Nomlabofusp
Nomlabofusp is a recombinant fusion protein designed to deliver human frataxin into the mitochondria of patients with Friedreich’s ataxia. The therapy is intended to address the underlying protein deficiency rather than only manage disease symptoms.
Accelerated-Approval Strategy
Larimar is working with the FDA on a BLA using skin frataxin as a biomarker and matched natural-history comparisons for clinical outcomes. A global confirmatory Phase 3 trial is planned to be underway at submission and uses change in the Upright Stability Score as its primary endpoint.
Platform Expansion
Beyond Friedreich’s ataxia, Larimar intends to use its intracellular delivery technology to create fusion proteins for other rare diseases caused by deficiencies in intracellular bioactive compounds.
未來催化劑
- Topline open-label nomlabofusp data expected in the second quarter of 2026.
- Start of screening for the confirmatory Phase 3 study expected in the second quarter of 2026, with first dosing around mid-2026.
- Nomlabofusp BLA submission seeking accelerated approval planned for June 2026.
- Potential U.S. launch targeted for the first half of 2027, subject to approval.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。